Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...

Discontinue and treat if paradoxical bronchospasm occurs; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders.